CTLA4 and neoplasm: The established anti-tumor activity of targeting the PD-1 signaling axis as a monotherapy in a variety of cancers coupled with a favorable toxicity profile when compared to CTLA-4 inhibition provided robust justification for selecting anti-PD-1 antibodies as the backbone of combinatorial strategies.